Anouk Waeytens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anouk Waeytens has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Debby Laukens
Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
3 shared publications Harald Peeters
2 shared publicationsMartine De Vos
Department of Gastroenterology, Ghent University, De Pintelaan 185, 9000 Gent, Belgium
2 shared publications- Bert Vander Cruyssen
Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
1 shared publication Claude A. Cuvelier
Department of Pathology, Ghent University, Ghent, Belgium
1 shared publication- Claude A. Cuvelier
Department of Pathology, Ghent University, Ghent, Belgium
1 shared publication
Latest Publications
- Open Access
- 26 August 2009
- Published by Hindawi Limited in Mediators of Inflammation
- Vol. 2009, 1-9
Evidence for a Potential Role of Metallothioneins in Inflammatory Bowel Diseases
Inflammatory bowel diseases (IBDs) are a group of chronic, relapsing, immune-mediated disorders of the intestine, including Crohn's disease and ulcerative colitis. Recent studies underscore the importance of the damaged epithelial barrier and the dysregulated innate immune system in their pathogenesis. Metallothioneins (MTs) are a family of small proteins with a high and conserved cysteine content that are rapidly upregulated in response to an inflammatory stimulus. Herein, we review the current knowledge regarding the expression and potential role of MTs in IBD. MTs exert a central position in zinc homeostasis, modulate the activation of the transcription factor nuclear factor (NF)-B, and serve as antioxidants. In addition, MTs could be involved in IBD through their antiapoptotic effects or through specific immunomodulating extracellular effects. Reports on MT expression in IBD are contradictory but clearly demonstrate a deviant MT expression supporting the idea that these aberrations in IBD require further clarification.
- 26 August 2009
- Published by Hindawi Limited in Mediators of Inflammation
- Vol. 2009, 1-9
Open AccessEvidence for a Potential Role of Metallothioneins in Inflammatory Bowel Diseases
Inflammatory bowel diseases (IBDs) are a group of chronic, relapsing, immune-mediated disorders of the intestine, including Crohn's disease and ulcerative colitis. Recent studies underscore the importance of the damaged epithelial barrier and the dysregulated innate immune system in their pathogenesis. Metallothioneins (MTs) are a family of small proteins with a high and conserved cysteine content that are rapidly upregulated in response to an inflammatory stimulus. Herein, we review the current knowledge regarding the expression and potential role of MTs in IBD. MTs exert a central position in zinc homeostasis, modulate the activation of the transcription factor nuclear factor (NF)-B, and serve as antioxidants. In addition, MTs could be involved in IBD through their antiapoptotic effects or through specific immunomodulating extracellular effects. Reports on MT expression in IBD are contradictory but clearly demonstrate a deviant MT expression supporting the idea that these aberrations in IBD require further clarification.
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5) , -244-244
S1657 Absence of Placental Growth Factor Aggravates DSS-Induced Acute Colonic Injury
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5) , -244-244
S1657 Absence of Placental Growth Factor Aggravates DSS-Induced Acute Colonic Injury
- 30 April 2008
- Published by Elsevier in Gastroenterology
- Vol. 134 (4)
M2045 Reduced Metallothionein Expression in Colonic Crohn's Disease: Evidence for a New Disease-Modifying Gene
- 30 April 2008
- Published by Elsevier in Gastroenterology
- Vol. 134 (4)
M2045 Reduced Metallothionein Expression in Colonic Crohn's Disease: Evidence for a New Disease-Modifying Gene
- Open Access
- 1 April 2008
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 14 (4) , 471-479
Paracellular entry of interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice
Background. Genetically modified Lactococcus lactis secreting interleukin-10 (IL-10) has been demonstrated to provide localized delivery of a therapeutic agent
- 1 April 2008
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 14 (4) , 471-479
Open AccessParacellular entry of interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice
Background. Genetically modified Lactococcus lactis secreting interleukin-10 (IL-10) has been demonstrated to provide localized delivery of a therapeutic agent